Vemurafenib Recruiting Phase 2 Trials for Metastatic Melanoma / Metastatic Melanoma, BRAF V600 Mutation Positive Screening

IndicationsStatusPurposePhase
RecruitingScreening2
clinicaltrials.gov IdentifierTitleDrugs
NCT02768207A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma